Harmony Biosciences (HRMY) to Release Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.84 per share and revenue of $240.0360 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $29.16 on Friday. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The firm has a market capitalization of $1.68 billion, a PE ratio of 9.17, a price-to-earnings-growth ratio of 0.27 and a beta of 0.84. The firm has a fifty day simple moving average of $37.03 and a two-hundred day simple moving average of $34.29. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Oppenheimer reiterated an “outperform” rating and set a $62.00 price target on shares of Harmony Biosciences in a research note on Monday, November 24th. HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, December 3rd. Mizuho set a $50.00 price target on shares of Harmony Biosciences in a report on Thursday. UBS Group lowered Harmony Biosciences from a “buy” rating to a “neutral” rating and raised their target price for the company from $43.00 to $46.00 in a research report on Wednesday, February 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $46.13.

Insider Activity

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Sandip Kapadia sold 3,746 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a total transaction of $139,163.90. Following the sale, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at $910,955.15. The trade was a 13.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 50,640 shares of company stock valued at $1,932,256. Company insiders own 23.60% of the company’s stock.

Institutional Trading of Harmony Biosciences

Hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in shares of Harmony Biosciences by 8.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,830,726 shares of the company’s stock worth $68,507,000 after buying an additional 139,145 shares during the last quarter. State Street Corp raised its stake in shares of Harmony Biosciences by 0.5% in the fourth quarter. State Street Corp now owns 1,661,850 shares of the company’s stock worth $62,186,000 after purchasing an additional 8,246 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Harmony Biosciences by 15.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,491,605 shares of the company’s stock valued at $55,816,000 after acquiring an additional 196,224 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Harmony Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 1,270,586 shares of the company’s stock worth $47,551,000 after acquiring an additional 12,323 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Harmony Biosciences by 128.9% during the fourth quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after purchasing an additional 458,321 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.